FDA Vaccine Chief Vinay Prasad Resigns After Controversial Tenure
Dr. Vinay Prasad, FDA's top vaccine official, resigned after a brief, controversial tenure, clashing over drug approvals, limiting Covid-19 vaccine use, and facing gene therapy scrutiny.
Overview
- Dr. Vinay Prasad, the FDA's top vaccine official, resigned after a brief tenure of less than four months, a departure confirmed by the Department of Health and Human Services.
- His controversial time at the FDA included his approach to drug approvals, which reportedly clashed with the preferences of Trump's Republican supporters.
- Prasad faced significant criticism and scrutiny for his decisions, notably pausing a gene therapy and his handling of a specific safety issue within the agency.
- During his short post, Dr. Prasad also limited the use of Covid-19 vaccines and declined therapies proposed by various biotech companies, drawing further attention.
- His actions, including cracking down on gene therapy companies, contributed to the contentious nature of his tenure before his resignation, with specific details undisclosed.
Report issue
Read both sides in 5 minutes each day
Analysis
Center-leaning sources frame the story by portraying the departing FDA vaccine chief as a "polarizing" and "contrarian" figure whose brief tenure was marked by significant controversy and political backlash. They emphasize his clashes with various groups and his "skeptical" approach to drug approvals, suggesting these factors led to his ouster rather than his stated reason for leaving.
"In his three-month tenure at the FDA, the agency decided to limit COVID-19 vaccine recommendations to people 65 years of age and older and others who are at high risk of becoming seriously ill if they are infected, and will require manufacturers to conduct clinical trials to show whether the vaccines are of benefit to healthy younger adults and children."
CBS News"Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure that drew the ire of biotech companies, patient groups and conservative allies of President Donald Trump."
ABC NewsArticles (5)
FAQ
Dr. Vinay Prasad resigned after a brief, controversial tenure marked by clashes over drug approvals, limiting Covid-19 vaccine use, and controversies surrounding gene therapy. Political backlash, including criticism from Trump supporters and issues related to a gene therapy dispute with Sarepta Therapeutics, contributed to his sudden departure. The Department of Health and Human Services stated he did not want to be a distraction to the FDA's work and decided to return to California to spend time with his family.
During his tenure, Dr. Prasad faced criticism for pausing a gene therapy treatment for Duchenne muscular dystrophy, limiting the use of Covid-19 vaccines, rejecting therapies proposed by biotech companies, and clashing with political figures and groups, especially Trump's Republican supporters.
Dr. Vinay Prasad served as the FDA's director of the Center for Biologics Evaluation and Research, overseeing vaccines, gene therapies, and blood products. He was also the agency’s chief medical and scientific officer, a top advisor to FDA Commissioner Marty Makary, roles that combined responsibilities of other high-ranking officials who had left under the Trump administration.
Political factors played a significant role; Dr. Prasad's decisions clashed with the preferences of Trump’s Republican supporters. He faced political backlash and social media campaigns against him, notably from right-wing influencers highlighting his past support for Democrats. This political tension was a contributing factor to his resignation.
Despite his short and contentious tenure, Dr. Prasad achieved several important reforms in regulatory processes related to vaccines and biologics, including a stricter review approach to drug approvals and limiting some COVID-19 vaccine applications. However, these changes were controversial and sparked significant debate within and outside the agency.
History
- This story does not have any previous versions.